Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Matt Stang was included in World Biz magazine’s Top-100 CEOs in Innovation for 2022. The announcement noted that Stang was recognized as a champion of creativity who is dedicated to making a positive environmental and social impact. Stand cofounded Delic Corp., which has grown into a … Continue reading “NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Makes Top-100 Innovation List, Company Postpones Meet Delic Event”
Silo Pharma (OTCQB: SILO) recently reported that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients. The psilocybin was administered “as part of a scientific research agreement (‘SRA’) entered with Silo in June 2021 to ‘determine the effects of psilocybin on inflammatory markers of patients … Continue reading “NetworkNewsBreaks – Silo Pharma Inc. (SILO) Fusing Traditional Therapeutics with Psychedelic Research”
Company entered scientific research agreement with UCSF in June 2021 to study psilocybin effects on various inflammatory conditions Silo Pharma (OTCQB: SILO), recently announced that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients as part of a scientific research agreement (“SRA”) entered with Silo … Continue reading “Silo Pharma Inc. (SILO): Promising Psylocibin Study Ongoing with UCSF”
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, have announced advanced appointments for two key executives. According to the company, Delic Holdings cofounder and CEO Matt Stang has been named executive chair while COO Kevin Nicholson has been named CEO and will also join … Continue reading “NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Key Management Positions”
Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery system Results of study demonstrated Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time point Ketamine typically used to induce and maintain … Continue reading “Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain”
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has completed the sale of 1,240 units, with each unit consisting of one 4% senior secured $1,064 principal amount convertible debenture and 16,369 share purchase warrants. The sale, which was resulted in gross proceeds of $1,240,000 for … Continue reading “NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Completion of Debenture Offering”
Silo Pharma (OTCQB: SILO) earlier this year extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). “Silo’s partnership with UMB focuses on peptides used for investigating and treating the arthritogenic … Continue reading “NetworkNewsBreaks – Silo Pharma Inc. (SILO), UMB Collaborating on Potentially Significant Homing-Peptide Technology”
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has released an update on its both its financial and corporate status. According to the announcement, the company released its first end-of-year earnings report in May, which showed $1.5 million annual revenue and a growth in … Continue reading “NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Reports on First Full-Year Revenue, Issues KWC Status Update”
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that Dr. Markus Roggen, president and chief science officer for Delic Labs, was named to the Cannabis Scientist Power List for the third consecutive year. Due to his commitment to creating a body of … Continue reading “NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Celebrates Third Recognition of Delic Labs’ Dr. Markus Roggen to Cannabis Scientist Power List”
Silo’s partnership with UMB could yield therapeutics that limit side effects through precisely targeted delivery On February 3, 2022, Silo Pharma (OTCQB: SILO) extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and … Continue reading “Homing Peptides: Silo Pharma Inc. (SILO) Targets ADRs”
